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Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) functions as a cytokine to selectively
kill various cancer cells without toxicity to most normal cells. Numerous studies have demonstrated the potential
use of recombinant soluble TRAIL as a cancer therapeutic agent. We have showed previous administration of a
recombinant adeno-associated virus (rAAV) vector expressing soluble TRAIL results in an efficient suppression of
human tumor growth in nude mice. In the present study, we introduced Tet-On gene expression system into the
rAAV vector to control the soluble TRAIL expression and evaluate the efficiency of the system in cancer gene
therapy.
Methods: Controllability of the Tet-On system was determined by luciferase activity assay, and Western blotting
and enzyme-linked immunoabsorbent assay. Cell viability was determined by MTT assay. The breast cancer
xenograft animal model was established and recombinant virus was administrated through tail vein injection to
evaluate the tumoricidal activity.
Results: The expression of soluble TRAIL could be strictly controlled by the Tet-On system in both normal and
cancer cells. Transduction of human cancer cell lines with rAAV-TRE-TRAIL&rAAV-Tet-On under the presence of
inducer doxycycline resulted in a considerable cell death by apoptosis. Intravenous injection of the recombinant
virus efficiently suppressed the growth of human breast carcinoma in nude mice when activated by doxycycline.
Conclusion: These data suggest that rAAV-mediated soluble TRAIL expression under the control of the Tet-On
system is a promising strategy for breast cancer therapy.
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Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) functions as a cytokine to selectively kill various
cancer cells without toxicity to most normal cells [1,2].
Numerous studies have demonstrated the potential use
of TRAIL as a cancer therapeutic and a number of
TRAIL gene therapy strategies using recombinant viral
vectors are described in the literature [3-19]. Our previ-
ous study showed that administration of the recombin-
ant adeno-associated virus (rAAV) vector expressing
soluble TRAIL (sTRAIL) results in efficient suppression* Correspondence: liuyx2000@tom.com; zhengdx@pumc.edu.cn
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reproduction in any medium, provided the orof tumor growth transplanted in the liver and lung of
mouse models [16-19].
However, the potential utility and safety of TRAIL has
been questioned because of its potential toxicity to nor-
mal cells and the mechanism of toxicity still hangs in
doubt. Several reports showed that recombinant soluble
TRAIL was toxic to normal liver cells [20], keratinocytes
[21], brain cells[22], prostate epithelial cells[23], as well
as neutrophils[24]. Furthermore, the physiological func-
tion of TRAIL is much less well understood. It was
reported that TRAIL plays a critical role in innate im-
munity, adaptive immunity, infectious diseases and auto-
immune diseases [25,26], suggesting that TRAIL serves
as an important immune regulatory factor under physio-
logical condition. Therefore, systemic over-expression ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions. We have shown previously that TRAIL can induce
secretion of inflammatory chemokines both in vitro and
in vivo [27,28]. In addition, a study indicated that
increased hepatic TRAIL expression was accompanied
by an increase in liver accumulation of natural killer cells
and natural killer T lymphocytes, therefore, mediated
liver injury by the innate immune system in certain
pathological conditions [29]. One of the key points in
successfully implementing gene therapy or biological
therapy in the clinical setting is to be able to regulate the
targeted gene expression strictly and consistently as and
when it is needed.
The Tet-On regulable gene expression system has been
widely known to optimize gene therapy strategies [30].
This system can switch targeted gene expression on and
off in the presence or absence of the inducer doxycycline
(Dox). In the on situation, upon delivery or presence of
Dox, reverse tetracycline transactivator (rtTA) activates
tetracycline responsive element (TRE) and induces tar-
geted gene expression. In the off situation, upon removal
or absence of Dox, rtTA impedes transcript initiation by
the TRE promoter.
In the present study we introduced the Tet-On system
into the rAAV vector (AAV-TRE-TRAIL&AAV-Tet-On)
to control the soluble TRAIL expression and evaluate its
efficiency in breast cancer gene therapy. Our data
demonstrated that the expression of sTRAIL could be
strictly controlled by the system in both normal and can-
cer cells. As a result the expression could be shut down
when side effects appear so as to avoid serious adverse
events. Moreover, the gene therapy suppressed breast
cancer growth in nude mice efficiently, suggesting that
AAV-mediated, Dox regulatable sTRAIL expression is a
promising strategy for cancer gene therapy.
Methods
Cell lines
MDA-MB-231 (human breast carcinoma) and A549
(human lung carcinoma) cell lines were purchased from
American Type Culture Collection (Rockville, MD).
HepG2 (hepatocellular carcinoma) was purchased from
the Cell Culture Center, Chinese Academy of Medical
Sciences (Beijing, China). Human hepatocellular carcin-
oma SMMC-7721 and SMMC-7402 cell lines were pur-
chased from the Institute of Cell and Biochemistry,
Chinese Academy of Sciences (Shanghai, China). These
cell lines were cultured in RPMI1640 medium (Gibco,
BRL). Human embryo kidney cell line HEK293T/17 was
originally purchased from ATCC (No. CRL 1573) and
maintained in Dulbecco’s Modified Eagle’s medium
(DMEM, Gibco, BRL). U251 (human glioma) was
obtained from the Cell Culture Center, Chinese Academy
of Medical Sciences (Beijing, China) and maintained inminimal essential medium (MEM) containing Earle’s
balanced salt solution (MEM-EBSS, Gibco, BRL). These
cells were cultured in the medium supplemented with
10% FBS (Hyclone Laboratories), 100 units/mL of peni-
cillin, 100 μg/mL of streptomycin, and 2 mmol/L of glu-
tamine at 37°C in a 5% CO2 incubator.
Generation of rAAV viral particles
Adeno-associated virus (AAV) vector, a safe vector with
fewer pathogenic effects that mediate a long-term tar-
geted gene expression, was used in this study. Recombin-
ant AAV (rAAV) plasmids were constructed using the
AAV2 expression vector (a gift from the University of
Hong Kong, Hong Kong) containing CAG (chicken β-
actin promoter plus cytomegalovirus enhancer) promoter
as the backbone. The TRE and CMV-rtTA fragments
were cut out from pTRE-tight and pTet-On (Clontech,
CA), respectively, and inserted into AAV2 to replace the
CAG protmoter. The cDNA encoding soluble TRAIL
was amplified by PCR and inserted into AAV2 expres-
sion vector under the control of TRE promoter. The
resulting constructs were designated as rAAV-TRE-
TRAIL&rAAV-Tet-On. The plasmid rAAV-TRE-EGFP
encoding enhanced green fluorescent protein (EGFP)
and rAAV-TRE-Luc encoding luciferase were con-
structed as controls. The constructs were validated by
DNA sequencing analysis. Packaging and purification of
the rAAV particles were performed as described previ-
ously[17]. Infectious AAV particles were generated in
human embryo kidney cells at a temperature of 37°C.
Titers of the rAAV particles were represented as genome
particles (Gps)/ml.
rAAV infection and induction of targeted gene expression
Cells were cultured at 1 × 104 cells per well in 96 well
plates or 2 × 105 cells per well in six well plates. The cells
were infected with rAAV particles for at least six hours
in serum-free and antibiotics-free medium. The ratio of
viral particles and cells was 2 × 105 Gps per cell. The
infected cells were incubated with or without 1 μg/ml
doxycycline (Dox) in complete medium for 24 h, 48 h,
72 h or 96 h, respectively. The relative light units of luci-
ferase gene expression were determined by Modulus
Microplate Multimode Reader. The GFP expression was
observed under a fluorescence microscope (Nikon
TE2000, JP). TRAIL expression was detected by Western
blot assay and ELISA with TRAIL/TNFSF10 immuno-
assay kit (Quantikine, R&D) according to the manufac-
turer instructions.
Cell viability assay
Cell viability was evaluated by MTT (3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide)
(Sigma, St. Louis, MO) assay. MTT assay was followed to
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ously[16].
Apoptosis assay
Apoptosis was detected with Annexin V-FITC/PI apop-
tosis detection kit (BD Biosciences, San Jose, CA)
according to the manufacturer’s instructions. Cells were
seeded in six-well plates at 2 × 105 cells per well. The
cells infected with rAAV-TRE-TRAIL&rAAV-Tet-On
were harvested 48 h post infection. Annexin V-FITC/PI
staining was performed as described previously[16].
RT-PCR and western blot analysis
Total RNA were extracted from the cells infected
with rAAV-TRE-TRAIL&rAAV-Tet-On, rAAV-TRE-EGF-
P&rAAV-Tet-On or rAAV-CAG-EGFP particles by using
TRIZOL reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. The transcriptional ex-
pression of WPRE, a characteristic sequence of rAAV
vector, regulated by TRE promoter in the cells was ana-
lyzed by RT-PCR representative of the targeted gene
TRAIL expression. Two micrograms of total RNAs were
used to synthesize cDNA in 20 μl reaction mixture with
oligo-(dT) as primer and M-MuLV reverse transcriptase
followed to manufacturer’s protocol (New England Biolabs,
Beverly, MA). Two micrograms of RT product and WPRE-
specific primers (5′-AAGATTGACTGGTATTCT-3′ and
5′-ATCCGACTCGTCTGAG-3′) were used in 20 μl reac-
tion mixtures for PCR to detect the transcriptional expres-
sion of TRAIL. β-actin was used as an internal control.
Western blot analyses were performed as described pre-
viously[16]. Rabbit polyclonal antibodies against human
TRAIL were pruchased from Santa Cruz Biotechnology
(sc-7877; Santa Cruz, CA).
Animal studies
All animal procedures were approved by the Committee
on the use and care of animals, Chinese Academy of
Medical Sciences (Beijing). Four week’s old female
BALB/c nude mice were recruited for the animal studies.
To evaluate the tumoricidal activity of rAAV-TRE-
TRAIL&rAAV-Tet-On, rAAV-CAG-TRAIL or rAAV-
TRE-EGFP&rAAV-Tet-On, a breast cancer xenograft
animal model was established by injecting 1 × 107 MDA-
MB-231 cells into mouse dorsal flanks. When the tumor
size reached about 50 mm3, the animals were divided
into three groups (n = 6) and intra-tail vein injections of
4 × 1011 Gps of rAAV-TRE-TRAIL&rAAV-Tet-On (TRE-
TRAIL group), rAAV-CAG-TRAIL (CAG-TRAIL group)
or rAAV-TRE-EGFP&rAAV-Tet-On (TRE-EGFP group)
particles were administered. The ratio of rAAV-TRE and
rAAV-Tet-On particles in TRE-TRAIL and TRE-EGFP
group was 1:1. Dox was added into the mouse drinking
water at a concentration of 1 mg/ml after injection.Tumor growth was observed every 4 days for 32 days by
measuring the two dimensional longest axis (a) and
shortest axis (b) with a caliper when the tumor was
macroscopic. The tumor volume was calculated by using
the following formula: volume in mm3= (ab2)/2. At the
end of experiment, the animals were sacrificed, tumors
and tissues were removed for RT-PCR and Western blot
analysis.
Statistics
Results of the data are reported as the mean ± standard
deviation (SD) and ANOVA for repeated data was used
to analyze the differences between the groups using stat-
istical software SPSS10.0. The significant level was
defined as p< 0.05.
Results
Controllable expression of target gene driven by tet-on
system
To evaluate a controllable gene expression of the target
gene driven by the Tet-On system, HEK293T/17 cells
were first transduced with the recombinant virus rAAV-
TRE-Luc&AAV-Tet-On at 2 × 105 Gps per cell.The rela-
tive light units representing luciferase activity in the cell
lysate were detected. As shown in Figure 1A, the lucifer-
ase activity in the cells induced with 1 μg/ml of doxcy-
cline (AAV-TRE-Luc&AAV-Tet-On/Dox+) was 70 fold
higher than the cells without Dox treatment (AAV-TRE-
Luc&AAV-Tet-On/ Dox-). However, there was no differ-
ence in the cells transduced with rAAV-TRE-Luc only
under the presence (Dox+) or absence (Dox-) of Dox.
This result was confirmed in the cells transduced with
AAV-TRE-EGFP&AAV-Tet-On (Figure 1B), in which
GFP expression driven by TRE and observed by fluores-
cence microscopy was as strong as that driven by CAG
in AAV-CAG-EGFP [17]. These data indicate that Tet-
On system can strictly control target gene expression
driven by TRE promoter.
Then, we examined the control capability and intensity
of the rAAV-mediated soluble TRAIL expression driven
by TRE promoter in the AAV-TRE-TRAIL&rAAV-Tet-
On recombinant virus. TRAIL expression in the cells
was detected by Western blot and soluble TRAIL
secreted in the media by ELISA. AAV-TRE-EGFP&AAV-
Tet-On and AAV-CAG-TRAIL were used as negative
control and positive control, respectively. As shown in
Figure 1C, the expression of sTRAIL was clearly
observed in HEK 293 T/17 cells transduced with rAAV-
TRE-TRAIL&AAV-Tet-On and induced by Dox (Dox+),
but not in those cells without Dox induction (Dox-). The
sTRAIL in the culture media of AAV-TRE-TRAI-
L&AAV-Tet-On/Dox+ was 469.9 pg/ml, while there was
no detectable sTRAIL in the media of AAV-TRE-TRAI-
L&AAV-Tet-On/Dox- (Figure 1D). These data suggest
Figure 1 AAV-TRE&AAV-Tet-On system regulates targeted gene expression. HEK293T/17 cells were infected with rAAV-TRE-Luc&AAV-Tet-On
or rAAV-TRE-Luc for 48 h, respectively. rAAV-CAG-EGFP were used as positive control. (A) The relative light units (RLU) representing luciferase
expression in the cells infected with rAAV-TRE-Luc&AAV-Tet-On/Dox+ were detemined on Modulus Microplate Multimode Reader. (B) The EGFP
expression in HEK293T/17 cells infected with rAAV-TRE-EGFP&AAV-Tet-On was observed by fluorescence microscopy (100 × magnification). (C)
TRAIL protein expression in HEK293T/17 cells infected with rAAV-TRE-TRAIL&AAV-Tet-On for 48 h was detected by Western blot assay. β-actin was
used as loading control. (D) Soluble TRAIL secreted into the medium of HEK293T/17 cells at 96 h after the transduction was determined by ELISA.
The cells infected with rAAV-TRE-EGFP&AAV-Tet-On were used as negative control. The cells infected with rAAV-CAG-TRAIL were used as positive
control. Dox+, 1 μg/ml doxycycline in cell culture medium. Dox-, without doxycycline in the medium.
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controls sTRAIL gene expression.
Tet-on system-controlled sTRAIL expression suppresses
tumor cell growth in vitro
To evaluate the ability of the Tet-On system-controlled
sTRAIL expression to suppress tumor cell growth, tumor
cell lines of MDA-MB-231, U251, SMMC-7721, SMMC-
7402, A549 and HepG2 were exposed for 24 h to the
supernatant of HEK293T cells that have been infected with
rAAV-TRE-TRAIL&AAV-Tet-On particles at 2 × 105 GPs
per cell for 72 h. Supernatant of HEK293T cells infected
with rAAV-TRE- EGFP&AAV-Tet-On and rAAV-CAG-
TRAIL were used as negative and positive control, respect-
ively. The viability of tumor cells was evaluated by MTT
assay. As shown in Figure 2A, the viability of MDA-MB-231, U251, SMMC-7721 and SMMC-7402 cells infected
with rAAV-TRE-TRAIL&AAV-Tet-On in the presence of
Dox decreased to 55%±1.4%, 52.9%±5.1%, 41.6%±6.4%
and 62.1%±1.4%, respectively. In contrast, the viability of
the cells infected with rAAV-TRE-TRAIL&AAV-Tet-On in
the absence of Dox was no change compared with the
negative control. We further demonstrated the viability
decrease in MDA-MB-231, U251, SMMC-7721 and
SMMC-7402 cells directly infected with rAAV-TRE-
TRAIL&AAV-Tet-On/Dox+ was correlated with the viral
infection (Figure 2B).
Apoptosis assay by Annexin V-FITC/PI double staining
followed by microscopy and flow cytometry showed that
while Dox induced-TRAIL expression was detected by
both RT-PCR and Western blot assay in U251 and
MDA-MB-231 cells (Figure 3A), tumor cell death by
Figure 2 Tet-On system-controlled sTRAIL expression induces apoptosis in tumor cells. (A) MDA-MB-231, U251, SMMC-7721, SMMC-7402,
A549 and HepG2 cells were exposed for 24 h to the supernatant of HEK293T cells that have infected with rAAV-TRE-TRAIL&AAV-Tet-On at 2 × 105
GPs per cell for 72 h. Supernatant of HEK293T cells infected with rAAV-TRE- EGFP&AAV-Tet-On and rAAV-CAG-TRAIL were used as negative and
positive control, respectively. Cell viability was measured by MTT assay. Results are presented as the mean± standard deviation of three individual
experiments in each group. Dox+, 1 μg/ml doxycycline in the cell culture medium; Dox-, without doxycycline in the medium. (B) Infection with
rAAV-TRE-TRAIL&AAV-Tet-On/Dox + induced apoptosis and the time course of virus infection.
Zheng et al. BMC Cancer 2012, 12:153 Page 5 of 9
http://www.biomedcentral.com/1471-2407/12/153apoptosis was occurred markedly (Figure 3B). These data
suggest that sTRAIL expression mediated by rAAV-TRE-
TRAIL&rAAV-Tet-On induces tumor cell death by
apoptosis, which is strictly regulated by Tet-On system.Tet-on system-controlled sTRAIL expression efficiently
suppresses human tumor growth in vivo
To test the tumor suppressing efficacy of rAAV-TRE-
TRAIL&rAAV-Tet-On in vivo, we established a xeno-
graft animal model in nude mice by subcutaneous trans-
plantation of MDA-MB-231 breast cancer cells, which
was relatively sensitive to the viral infection. When the
tumor size reached about 50 mm3, the animals were
divided into six groups (Table. 1, n = 6). The rAAV-TRE-
TRAIL&rAAV-Tet-On particles of 4 × 1011 Gps were
administered through tail vein injection and the animals
were given drinking water with or without Dox. The
tumor growth was observed by measuring the tumor size
every four days for a total of 32 days. The rAAV-TRE-EGFP&rAAV-Tet-On and rAAV-CAG-TRAIL particles
were administrated as negative and positive control, re-
spectively. As shown in Figure 4A, tumor volumes and
weights in the Dox+ group were smaller than that in the
Dox- group (p< 0.05). Furthermore, the therapeutic effi-
cacy in Dox+ group was similar to the rAAV-CAG-
TRAIL positive control. Western blot analysis showed
the presence of sTRAIL protein in tumor tissue and liver
in the animals of Dox+ group, but not in those of Dox-
group (Figure 4B). These data indicate that Dox-induced
sTRAIL expression suppresses subcutaneous breast can-
cer growth significantly.Tet-on system-controlled sTRAIL expression induces
tumor cell death in vivo by apoptosis via classic apoptosis
pathway
To explore the mechanism of tumor growth suppression
mediated by rAAV-TRE- TRAIL&rAAV-Tet-On infec-
tion, cleavage of pro-caspases, a hallmark of cell death by
Figure 3 Tet-On system-controlled sTRAIL expression suppresses tumor cell growth by apoptosis. MDA-MB-231 and U251 cells were
transduced for 48 h with rAAV-TRE-TRAIL&AAV-Tet-On at 2 × 105 GPs per cell. rAAV-TRE- EGFP&AAV-Tet-On and rAAV-CAG-TRAIL were used as
negative and positive control, respectively. (A) The sTRAIL expression was detected by RT-PCR and Western blot assay. (B) The viability of tumor
cells was evaluated by microscopy and flow cytometry. Dox+, 1 μg/ml doxycycline in the medium. Dox-, without doxycycline in the medium.
WPRE, woodchuck hepatitis virus posttranscriptional regulatory element, represents sTRAIL mRNA expression. NTC: No-Template Control. PTC:
Positive Template Control.
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was further detected by Western blot analysis. As shown
in Figure 5, rAAV-TRE-TRAIL&rAAV-Tet-On adminis-
tration and Dox induction resulted in the cleavage of
procaspase-3 and procaspase-8, but not in the animalsTable 1 Animal groups and administration
Animal Group Administration Dox* n
TRE-EGFP+ AAV-TRE-EGFP&AAV-Tet-On + 6
TRE-EGFP - AAV-TRE-EGFP &AAV-Tet-On – 6
TRE-TRAIL+ AAV-TRE-TRAIL&AAV-Tet-On + 6
TRE-TRAIL- AAV-TRE-TRAIL&AAV-Tet-On – 6
CAG-TRAIL+ AAV-CAG-TRAIL + 6
CAG-TRAIL- AAV-CAG-TRAIL - 6
* Dox+, 1 mg/ml in drinking water; Dox-, without Dox in drinking water.without Dox in the water, indicating that Tet-On sys-
tem-controlled sTRAIL expression in the animals
induces tumor cell death by apoptosis via the classic
apoptosis pathway characterized by caspase activation.Discussion
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a target for cancer therapy because of its abil-
ity to induce apoptosis in malignant cells while not in
most normal cells and tissues. However, its potential tox-
icity on some normal human cells (e.g. hepatocytes) has
been questioned, but the mechanism of the related tox-
icity still hangs in doubt. Furthermore, the physiological
function of TRAIL is much less well understood. From a
clinical point of view, one of the key issues in success-
fully implementing cancer gene therapies or biological
Figure 4 Tet-On system-controlled sTRAIL expression suppresses the growth of MDA-MB-231 xenografts in nude mice. A xenograft
MDA-MB-231 animal model was established in nude mice by subcutaneous transplantation. When the tumor size reached to about 50 mm3
(about 7 days post-inoculation), the animals were divided into six groups (n = 6). The rAAV-TRE-TRAIL&rAAV-Tet-On particles of 4 × 1011 Gps were
administered through tail vein injection and the animals (day 0) were fed with drinking water with or without doxycycline (1 mg/ml). (A) The
tumor growth was observed by measuring the tumor size every four days for total 32 days. The rAAV-TRE-EGFP&rAAV-Tet-On and rAAV-CAG-TRAIL
particles were administered as negative and positive control, respectively. The animals were sacrificed and the tumor weights (A) were measured
32 days after virus administration (day 32). Results are presented as the mean± standard deviation of 6 mice in each group. *P <0.05. (B) The
sTRAIL expression in tumor tissue was examined by reverse transcriptional PCR and Western blot assay. β-actin served as protein loading control.
WPRE, woodchuck hepatitis virus posttranscriptional regulatory element, representing sTRAIL mRNA expression. NTC: No-Template Control. PTC:
Positive Template Control.
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gene expression strictly and consistently as and when it
is needed.
In the present study, we introduced the Tet-On regulata-
ble gene expression system into rAAV vector (AAV-TRE-
TRAIL&AAV-Tet-On) to control the soluble TRAIL ex-
pression and evaluate the efficacy in cancer gene therapy.
We observed that the expression and secretion of sTRAIL
could be strictly controlled by the Tet-On system in both
normal and cancer cells. Transduction of various cancer
cell lines with AAV-TRE-TRAIL&AAV-Tet-On under the
presence of Dox resulted in significant cell death byapoptosis in SMMC-7721, SMMC-7402 liver cancer cells,
and A549 lung cancer cells, but not in HepG2 liver cancer
cells (Figure 2A). The resistance of HepG2 to AAV-TRE-
TRAIL&AAV-Tet-On might be a result of inefficient of
rAAV transduction or intracellular distinguishable events
with TRAIL and its receptors in the cells.
Intravenous injection of rAAV in the cancer mouse
models showed that sTRAIL protein was predominantly
expressed in liver and tumor tissue under induction con-
dition (Figure 4B). The tumor weights and volumes were
obviously smaller in the animals fed with Dox compared
with those without Dox. As a result, the expression could
Figure 5 Tet-On system-controlled sTRAIL expression induces
tumor cell apoptosis in vivo. The xenograft tumor cells were
isolated from the animals administered with rAAV-TRE-TRAIL&rAAV-
Tet-On and lyzed with lysis buffer. 400 micrograms of total protein in
the lysed were subjected to SDS-PAGE. Cleavage of procaspase-8
and procaspase-3 were examined by Western blot assay using
corresponding specific antibodies. β-actin was used as loading
control. The tumor lysates from the animals administrated with
rAAV-TRE-EGFP&rAAV-Tet-On and rAAV-CAG-TRAIL were used as
negative and positive control, respectively.
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serious adverse events.
To confirm whether there is an excellent target gene ex-
pression mediated by the AAV vector with the Tet-On
gene expression system, we established a positive control
of rAAV vectors with a CAG promoter, which has shown
a good performance in AAV-mediated gene therapy
[17,18]. Data in our research showed the intensity of
rAAV-TRE&rAAV-Tet-On mediated target gene expres-
sion under the induction condition was similar to that of
rAAV-CAG, indicating that the Tet-On gene expression
system has considerable capacity in controlling target gene
expression.
The Tet-On system offers many advantages over other
regulable gene expression systems [30]. The inducer
Dox, an analogue of tetracycline, has been used as an
antibiotic for decades and it has been well characterized
in the clinical setting. It is nontoxic at doses required for
gene activation in preclinical and clinical studies, and the
margin of safety is high. Dox is metabolized and cleared
from the body rapidly, making it an ideal drug for therapid increase in expression, long-term expression, and
rapid decrease in expression of the desired transgene.
The components of the Tet-On system recognizes
unique fragment of DNA, and Dox does not interfere
with native proteins, reducing the potential of serious
side effects.
However, a limitation of the approach is that two AAV
vectors were used as a mixture. One contained TRAIL
regulated by TRE, and the second contained rtTA acti-
vated by Dox. If the two AAV do not co-localize equally
in tumors, then TRAIL mediated killing would not be
optimized. Many researchers have attempted to con-
struct TRE and rtTA into one vector to improve the
efficiency of gene transduction. We also tried this ap-
proach to ligate rtTA, TRE promoter and TRAIL gene in
the rAAV vector, therefore, forms a single rAAV vector,
expecting to improve the expression intensity of the
transgene. However, this approach challenges the limits
of rAAV packaging capacity and causes difficulties in
virus packaging. In addition, we found that the cells
transduced with the single vector express the transgene
in the absence of Dox (data not shown), known as gene ex-
pression leakage in regulable gene expression system. In-
stead, a dual rAAV vector system in which the TRE-
TRAIL and rtTA were constructed into two rAAV vectors
respectively provided a similar intensity in transgene ex-
pression and much more strict controllability compared
with the single vector system.
Conclusions
We provided evidence in this study that the expression
of soluble TRAIL could be strictly controlled by the Tet-
On system both in vitro and in vivo; the expression
could be shut down when side effects appear to avoid
potential serious adverse events. Intravenous injection of
the recombinant virus efficiently suppressed the growth
of human breast carcinoma in nude mice. AAV-mediated
sTRAIL expression under the control of Tet-On system
is a promising strategy for cancer biological therapy.
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